Issue 8, 2021

Design and organocatalytic synthesis of spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors

Abstract

A collection of spirooxindole–cyclopentene–isoxazole hybrids bearing multiple chiral centers and various groups as potential MDM2–p53 inhibitors were designed and synthesized via a rarely reported organocatalytic 1,6-cycloaddition with exclusive α-regioselectivity. In vitro MDM2 binding and cytotoxicity assays showed that compound 4z was the most potent MDM2 inhibitor, while a mechanistic study indicated that oxidative damage and apoptosis in p53-wild colorectal cancer cells were induced. Molecular docking suggested that the H-bonds with Leu54 and pi stacking with His96 were crucial interactions between 4z and the substrate binding site of MDM2. This article demonstrates an efficient protocol to design and synthesize potent biologically active compounds, providing a basis for developing novel MDM2 inhibitors.

Graphical abstract: Design and organocatalytic synthesis of spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors

Supplementary files

Article information

Article type
Research Article
Submitted
24 Dec 2020
Accepted
08 Feb 2021
First published
18 Feb 2021

Org. Chem. Front., 2021,8, 1836-1843

Design and organocatalytic synthesis of spirooxindole–cyclopentene–isoxazole hybrids as novel MDM2–p53 inhibitors

X. Xie, S. Xiong, X. Li, H. Huang, F. Wu, P. Shen, C. Peng, G. He and B. Han, Org. Chem. Front., 2021, 8, 1836 DOI: 10.1039/D0QO01626H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements